Sugi Predict

Sugi Predict / Compounds / SCHEMBL799894

SCHEMBL799894

SCHEMBL799894

CC(C)(C)c1cc(Cl)ccc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 3/20 0.48
▸ TSHR P16473 5/20 0.44
▸ CYP3A4 P08684 3/20 0.44
▸ MAPK1 P28482 3/20 0.44
▸ TDP1 Q9NUW8 2/20 0.44
▸ ALDH1A1 P00352 4/20 0.42
▸ HSD17B10 Q99714 2/20 0.42
▸ LMNA P02545 3/20 0.40
▸ HTT P42858 1/20 0.40
▸ KDM4E B2RXH2 3/20 0.38
▸ NR1H4 Q96RI1 2/20 0.38
▸ GAA P10253 1/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ PDK1 Q15118 1/20 0.36
▸ PDK2 Q15119 1/20 0.36
▸ PDK3 Q15120 1/20 0.36
▸ PDK4 Q16654 1/20 0.36
▸ CCR2 P41597 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13403326 0.82 MAPK1 (0.46) TP53TSHRCYP3A4MAPK1TDP1
SCHEMBL11790248 0.81 TSHR (0.44) TP53TSHRCYP3A4MAPK1TDP1
SCHEMBL16579383 0.81 TSHR (0.44) TP53TSHRCYP3A4MAPK1TDP1
SCHEMBL30017641 0.81 TSHR (0.44) TP53TSHRCYP3A4MAPK1TDP1
SCHEMBL11793705 0.81 TP53 (0.44) TP53TSHRCYP3A4MAPK1TDP1
SCHEMBL799844 0.80 TSHR (0.62) TP53TSHRCYP3A4MAPK1TDP1
SCHEMBL803633 0.78 SMN1; SMN2 (0.44) TP53TSHRMAPK1TDP1ALDH1A1
SCHEMBL10610735 0.78 ALDH1A1 (0.43) TSHRTDP1ALDH1A1HSD17B10LMNA
SCHEMBL6763833 0.78 MAPK1 (0.39) TP53TSHRCYP3A4MAPK1TDP1
SCHEMBL5744183 0.78 CYP3A4 (0.48) TSHRCYP3A4MAPK1TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6566488-B2 Chloroform soluble content is at most 0.5% by weight; injection molded car parts; well balanced properties of fluidity, flexural strength and impact resistance. IDEMITSU KOSAN CO., LTD. (JP) 2003-05-20 — — US claimed
EP-4479479-B1 SILPHENYLENE POLYMERS WACKER CHEMIE AG (DE) 2025-08-13 — — EP disclosed
CN-119256051-A Silicon phenylene Polymer 瓦克化学股份公司 2025-01-03 — — CN disclosed
EP-4479479-A1 SILPHENYLENE POLYMERS Wacker Chemie AG (DE) 2024-12-25 — — EP disclosed
WO-2023222203-A1 SILPHENYLENE POLYMERS WACKER CHEMIE AG (DE) 2023-11-23 — — WO disclosed
US-11786528-B2 Pyrazolopyrimidine compounds as adenosine receptor antagonists EXSCIENTIA LTD. (GB) 2023-10-17 — — US disclosed
US-11786528-B2 Pyrazolopyrimidine compounds as adenosine receptor antagonists EXSCIENTIA LTD. (GB) 2023-10-17 — — US disclosed
US-20230271939-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS IP2IPO INNOVATIONS LIMITED (GB) 2023-08-31 — — US disclosed
US-20230271939-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS IP2IPO INNOVATIONS LIMITED (GB) 2023-08-31 — — US disclosed
US-20230250082-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS IP2IPO INNOVATIONS LIMITED (GB) 2023-08-10 — — US disclosed
US-20070027321-A1 Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME CORP. 2007-02-01 — — US disclosed
US-20060241172-A1 Benzodioxane and benzodioxolane derivatives and uses thereof WYETH (US) 2006-10-26 — — US disclosed
US-20060241172-A1 Benzodioxane and benzodioxolane derivatives and uses thereof WYETH (US) 2006-10-26 — — US disclosed
US-20040152736-A1 Thrombin receptor antagonists TOPROL ACQUISITION LLC 2004-08-05 — — US disclosed
US-20040152736-A1 Thrombin receptor antagonists TOPROL ACQUISITION LLC 2004-08-05 — — US disclosed
US-6566488-B2 Chloroform soluble content is at most 0.5% by weight; injection molded car parts; well balanced properties of fluidity, flexural strength and impact resistance. IDEMITSU KOSAN CO., LTD. (JP) 2003-05-20 — — US disclosed
US-6489437-B2 WELL-BALANCED FLUIDITY AND MECHANICAL STRENGTH. IDEMITSU KOSAN CO., LTD. (JP) 2002-12-03 — — US disclosed
US-20020128372-A1 Polyarylensulfide, polyarylensulfide resin composition, method for producing polyarylensulfide IDEMITSU KOSAN CO., LTD. (JP) 2002-09-12 — — US disclosed
US-20020062003-A1 POLYARYLENE SULFIDE RESIN COMPOSITION IDEMITSU KOSAN CO., LTD. (JP) 2002-05-23 — — US disclosed
US-6388003-B1 MIXTURE CONTAINING FILLER IDEMITSU KOSAN CO., LTD. (JP) 2002-05-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271939-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS EIF2AK4, GCN1, EIF5B TP53 2921/4885TSHR 4759/4885CYP3A4 647/4885
US-11786528-B2 Pyrazolopyrimidine compounds as adenosine receptor antagonists ADORA1, ADORA3, ADORA2A TP53 1738/4885TSHR 258/4885CYP3A4 135/4885
US-20230250082-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS EIF2AK4, GCN1, EIF5B TP53 2921/4885TSHR 4759/4885CYP3A4 647/4885
US-20060241172-A1 Benzodioxane and benzodioxolane derivatives and uses thereof HTR2C, HTR1D, HTR1A TP53 4185/4885TSHR 216/4885CYP3A4 284/4885
US-20040152736-A1 Thrombin receptor antagonists CNR1, TBXA2R, CNR2 TP53 3802/4885TSHR 97/4885CYP3A4 342/4885
US-20070027321-A1 Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRM1 TP53 4883/4885TSHR 692/4885CYP3A4 1798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.